Cargando…

Difference in Neutropenia due to Administration Schedule of TAS-102

TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the ad...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Yoichiro, Aisu, Naoya, Mogi, Ai, Komono, Akira, Sakamoto, Ryohei, Kojima, Daibo, Mera, Toshiyuki, Hasegawa, Suguru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2017
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5465677/ https://www.ncbi.nlm.nih.gov/pubmed/28611635 http://dx.doi.org/10.1159/000460242

Ejemplares similares

Phase 2 study of perioperative chemotherapy with SOX and surgery for stage III colorectal cancer (SOS3 study)
por: Aisu, Naoya, et al.
Publicado: (2019)

Evaluation of vascular pain in patients with colorectal cancer receiving peripheral venous chemotherapy with or without oxaliplatin
por: Matsuoka, Taisuke, et al.
Publicado: (2019)

Phase II study on early start of chemotherapy after excising primary colorectal cancer with distant metastases (Pearl Star 02)
por: Yoshida, Yoichiro, et al.
Publicado: (2017)

Objective evaluation of oxaliplatin-induced vascular pain secondary to peripheral vein administration
por: Yoshida, Yoichiro, et al.
Publicado: (2016)

Transanal TME: new standard or fad?
por: Hasegawa, Suguru, et al.
Publicado: (2019)

A Trial Protocol of Biweekly TAS-102 and Bevacizumab as Third-Line Chemotherapy for Advanced/Recurrent Colorectal Cancer: A Phase II Multicenter Clinical Trial (The TAS-CC4 Study)
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

Drug-induced Pneumonitis Following the Administration of TAS-102
por: Hasegawa, Yoshikazu, et al.
Publicado: (2016)

Reconstruction with omental flap and negative pressure wound therapy after total pelvic exenteration of anal fistula cancer: a case report
por: Komono, Akira, et al.
Publicado: (2022)

The Relationship Between Evaluation Methods for Chemotherapy-Induced Peripheral Neuropathy
por: Yoshida, Yoichiro, et al.
Publicado: (2019)

Relationship between perioperative oncological evaluation and recurrence using circulating tumor DNA with KRAS mutation in patients with colorectal cancer
por: Hayashi, Takaomi, et al.
Publicado: (2022)

Combined laparoscopic and transperineal endoscopic total pelvic exenteration for the vaginal stump recurrence of cervical cancer
por: Ohno, Ryo, et al.
Publicado: (2021)

5-Nitrouracil stabilizes the plasma concentration values of 5-FU in colorectal cancer patients receiving capecitabine
por: Yoshida, Yoichiro, et al.
Publicado: (2020)

Oncological evaluation in the perioperative period using cfDNA with BRAF V600E mutation in patients with colorectal cancer
por: Tanaka, Keita, et al.
Publicado: (2021)

TAS-102 and the quest for predictive biomarkers
por: van der Velden, Daphne L, et al.
Publicado: (2017)

Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer
por: Sugiura, Kiyoaki, et al.
Publicado: (2021)

Prognostic impact of severe neutropenia in colorectal cancer patients treated with TAS-102 and bevacizumab, addressing immortal-time bias
por: Watanabe, Daichi, et al.
Publicado: (2023)

Detection of carbon dioxide embolism by transesophageal echocardiography during transanal/perineal endoscopic surgery: a pilot study
por: Matsumoto, Yoshiko, et al.
Publicado: (2022)

Subjective and objective assessment of oxaliplatin-induced peripheral neuropathy
por: Yoshida, Yoichiro, et al.
Publicado: (2015)

A Comparison of Bevacizumab Plus TAS-102 and TAS-102 Monotherapy for Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis
por: Chen, Xiaochen, et al.
Publicado: (2021)

Effect of food on the pharmacokinetics of TAS‐102 and its efficacy and safety in patients with advanced solid tumors
por: Yoshino, Takayuki, et al.
Publicado: (2016)

Prophylactic use of pegfilgrastim enables the management of severe neutropenia without dose delays in patients with metastatic colorectal cancer treated with TAS-102 plus bevacizumab
por: Tamaki, Sawako, et al.
Publicado: (2022)

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
por: Bendell, Johanna C., et al.
Publicado: (2016)

TAS-102, the first “cardio-gentle” fluoropyrimidine in the colorectal cancer landscape?
por: Petrelli, Fausto, et al.
Publicado: (2016)

TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
por: Liu, Cheng-Jiang, et al.
Publicado: (2021)

Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: a cohort study
por: Kasi, Pashtoon M., et al.
Publicado: (2016)

Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours
por: Doi, T, et al.
Publicado: (2012)

Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

Efficacy and safety of TAS-102 in refractory metastatic colorectal cancer: a meta-analysis
por: Chen, Duke, et al.
Publicado: (2018)

Hospitalizations and Clinical Outcome in Metastatic Colorectal Cancer During Regorafenib or TAS-102 Therapy
por: Huemer, Florian, et al.
Publicado: (2020)

Tas-102 for Refractory Metastatic Colorectal Cancer: A Multicenter Retrospective Cohort Study
por: Conti, Matteo, et al.
Publicado: (2023)

Erratum to: Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer
por: Bendell, Johanna C., et al.
Publicado: (2015)

A meta-analysis comparing regorafenib with TAS-102 for treating refractory metastatic colorectal cancer
por: Su, Guan-Li, et al.
Publicado: (2020)

Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models
por: TANAKA, NOZOMU, et al.
Publicado: (2014)

Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer
por: Kotani, Daisuke, et al.
Publicado: (2019)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Phase I study of TAS-102 and irinotecan combination therapy in Japanese patients with advanced colorectal cancer
por: Doi, Toshihiko, et al.
Publicado: (2015)

Interstitial pneumonia in a patient treated with TAS-102 for metastatic colorectal cancer: a case report
por: Kamei, Hideki, et al.
Publicado: (2016)

Complete response to third-line treatment with trifluridine/tipiracil (TAS-102) in stage IV colon adenocarcinoma
por: Lara-Morga, Celia, et al.
Publicado: (2023)

Expansion of transplanted islets in mice by co-transplantation with adipose tissue-derived mesenchymal stem cells
por: Tanaka, Tomoko, et al.
Publicado: (2018)

Dose Schedule Optimization and the Pharmacokinetic Driver of Neutropenia
por: Patel, Mayankbhai, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_jlsvetfcd3d2h34qnp13cp83ge